期刊
ANNALS OF ONCOLOGY
卷 23, 期 7, 页码 1713-1722出版社
OXFORD UNIV PRESS
DOI: 10.1093/annonc/mdr561
关键词
adjuvant chemotherapy; CA19; 9; pancreatic cancer; prognosis
类别
资金
- Gastroenterological Society of Australia (GESA)
- University of New South Wales
- National Health and Medical Research Council of Australia (NHMRC) [631701]
- The Cancer Council NSW [ICGC09-01]
- St Vincent's Clinic Foundation
- Royal Australasian College of Surgeons
- Australian Cancer Research Foundation
- R. T. Hall Trust
- The Avner Nahmani Pancreatic Cancer Research Fund
- Cancer Institute NSW [10/CRF/1-01]
Current staging methods for pancreatic cancer (PC) are inadequate, and biomarkers to aid clinical decision making are lacking. Despite the availability of the serum marker carbohydrate antigen 19.9 (CA19.9) for over two decades, its precise role in the management of PC is yet to be defined, and as a consequence, it is not widely used. We assessed the relationship between perioperative serum CA19.9 levels, survival and adjuvant chemotherapeutic responsiveness in a cohort of 260 patients who underwent operative resection for PC. By specifically assessing the subgroup of patients with detectable CA19.9, we identified potential utility at key clinical decision points. Low postoperative CA19.9 at 3 months (median survival 25.6 vs 14.8 months, P = 0.0052) and before adjuvant chemotherapy were independent prognostic factors. Patients with postoperative CA 19.9 levels > 90 U/ml did not benefit from adjuvant chemotherapy (P = 0.7194) compared with those with a CA19.9 of < 90 U/ml (median 26.0 vs 16.7 months, P = 0.0108). Normalization of CA19.9 within 6 months of resection was also an independent favorable prognostic factor (median 29.9 vs 14.8 months, P = 0.0004) and normal perioperative CA19.9 levels identified a good prognostic group, which was associated with a 5-year survival of 42%. Perioperative serum CA19.9 measurements are informative in patients with detectable CA19.9 (defined by serum levels of > 5 U/ml) and have potential clinical utility in predicting outcome and response to adjuvant chemotherapy. Future clinical trials should prioritize incorporation of CA19.9 measurement at key decision points to prospectively validate these findings and facilitate implementation.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据